NASDAQ : NRSN
NeuroSense Therapeutics Ltd. — Financial statements
Healthcare · Biotechnology · Israel
Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 4.86M | 4.86M | 4.20M | 4.78M | 4.97M | 1.59M |
| Research & Development | 6.23M | 6.23M | 5.70M | 7.27M | 5.59M | 1.39M |
| Operating Expenses | 11.09M | 11.09M | 9.90M | 12.05M | 10.55M | 2.98M |
| Operating Income | -11.09M | -11.09M | -9.90M | -12.05M | -10.55M | -2.98M |
| Interest & Investment Income | 13.00K | 13.00K | 2.00K | 178.00K | 91.00K | |
| Currency Exchange Gain (Loss) | -47.00K | -47.00K | -45.00K | 21.00K | -22.00K | -33.00K |
| Other Non Operating Income (Expenses) | -6.00K | -6.00K | -265.00K | 1.74M | -7.00K | -202.00K |
| Pretax Income | -11.12M | -11.12M | -10.21M | -10.11M | -10.49M | -3.22M |
| Net Income | -11.12M | -11.12M | -10.21M | -10.11M | -10.49M | -3.22M |
| Net Income to Common | -11.12M | -11.12M | -10.21M | -10.11M | -10.49M | -3.22M |
| Shares Outstanding (Basic) | 1.27M | 1.27M | 930.10K | 682.01K | 575.23K | 312.17K |
| Shares Outstanding (Diluted) | 1.27M | 1.27M | 930.10K | 682.01K | 575.23K | 312.17K |
| EPS (Basic) | -8.73 | -8.73 | -10.98 | -14.82 | -18.24 | -10.31 |
| EPS (Diluted) | -8.73 | -8.73 | -10.98 | -14.82 | -18.24 | -10.31 |
| Free Cash Flow | -7.68M | -7.68M | -10.14M | -8.38M | -7.69M | -1.56M |
| Free Cash Flow Per Share | -6.03 | -6.03 | -10.90 | -12.29 | -13.36 | -4.98 |
| EBITDA | -11.07M | -11.07M | -9.88M | -12.03M | -10.54M | -2.98M |
| D&A For EBITDA | 16.00K | 16.00K | 22.00K | 21.00K | 12.00K | 3.00K |
| EBIT | -11.09M | -11.09M | -9.90M | -12.05M | -10.55M | -2.98M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 166.00K | 166.00K | 3.38M | 2.64M | 3.54M | 11.06M |
| Short-Term Investments | 3.55M | |||||
| Cash & Short-Term Investments | 166.00K | 166.00K | 3.38M | 2.64M | 7.09M | 11.06M |
| Other Receivables | 33.00K | 33.00K | 164.00K | 166.00K | 131.00K | 178.00K |
| Receivables | 33.00K | 33.00K | 164.00K | 166.00K | 131.00K | 178.00K |
| Inventory | 452.00K | 452.00K | 738.00K | |||
| Prepaid Expenses | 80.00K | 80.00K | 87.00K | 70.00K | 124.00K | 132.00K |
| Other Current Assets | 47.00K | 47.00K | 35.00K | 40.00K | 36.00K | 39.00K |
| Total Current Assets | 778.00K | 778.00K | 4.40M | 2.92M | 7.38M | 11.41M |
| Property, Plant & Equipment | 228.00K | 228.00K | 150.00K | 247.00K | 313.00K | 19.00K |
| Other Long-Term Assets | 22.00K | 22.00K | 23.00K | 22.00K | 23.00K | |
| Total Assets | 1.03M | 1.03M | 4.58M | 3.19M | 7.72M | 11.43M |
| Accounts Payable | 799.00K | 799.00K | 1.16M | 1.46M | 498.00K | 39.00K |
| Accrued Expenses | 1.62M | 1.62M | 759.00K | 1.93M | 1.16M | 558.00K |
| Current Portion of Leases | 98.00K | 98.00K | 73.00K | 69.00K | 64.00K | |
| Total Current Liabilities | 2.52M | 2.52M | 1.99M | 3.46M | 1.73M | 597.00K |
| Long-Term Leases | 72.00K | 72.00K | 73.00K | 147.00K | ||
| Other Long-Term Liabilities | 1.41M | 1.83M | ||||
| Total Liabilities | 2.59M | 2.59M | 1.99M | 4.94M | 1.87M | 2.42M |
| Additional Paid-In Capital | 46.23M | 46.23M | 39.24M | 24.36M | 21.86M | 17.45M |
| Retained Earnings | -47.78M | -47.78M | -36.66M | -26.12M | -16.01M | -8.45M |
| Shareholders' Equity | -1.56M | -1.56M | 2.58M | -1.76M | 5.84M | 9.01M |
| Total Liabilities & Equity | 1.03M | 1.03M | 4.58M | 3.19M | 7.72M | 11.43M |
| Total Debt | 170.00K | 170.00K | 73.00K | 142.00K | 211.00K | |
| Net Cash (Debt) | -4.00K | -4.00K | 3.31M | 2.50M | 6.88M | 11.06M |
| Net Cash Per Share | -0.00 | -0.00 | 3.55 | 3.66 | 11.96 | 35.44 |
| Filing Date Shares Outstanding | 1.77M | 1.77M | 1.20M | 780.10K | 589.55K | 547.18K |
| Total Common Shares Outstanding | 1.63M | 1.63M | 1.16M | 768.95K | 589.10K | 547.18K |
| Working Capital | -1.74M | -1.74M | 2.41M | -543.00K | 5.66M | 10.81M |
| Book Value Per Share | -0.96 | -0.96 | 2.22 | -2.29 | 9.92 | 16.46 |
| Tangible Book Value | -1.56M | -1.56M | 2.58M | -1.76M | 5.84M | 9.01M |
| Tangible Book Value Per Share | -0.96 | -0.96 | 2.22 | -2.29 | 9.92 | 16.46 |
| Machinery | 131.00K | 131.00K | 123.00K | 120.00K | 91.00K | 24.00K |
| Leasehold Improvements | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -11.12M | -11.12M | -10.21M | -10.11M | -10.49M | -3.22M |
| Depreciation & Amortization | 16.00K | 16.00K | 22.00K | 21.00K | 12.00K | 3.00K |
| Loss (Gain) From Sale of Assets | 8.00K | |||||
| Stock-Based Compensation | 2.14M | 2.14M | 557.00K | 1.54M | 1.73M | 1.22M |
| Other Operating Activities | -46.00K | -46.00K | 277.00K | -1.72M | 41.00K | 180.00K |
| Change in Accounts Payable | -361.00K | -361.00K | -299.00K | 961.00K | 459.00K | -16.00K |
| Change in Other Net Operating Assets | 1.71M | 1.71M | -482.00K | 952.00K | 636.00K | 289.00K |
| Operating Cash Flow | -7.67M | -7.67M | -10.13M | -8.35M | -7.62M | -1.54M |
| Capital Expenditures | -8.00K | -8.00K | -3.00K | -29.00K | -70.00K | -17.00K |
| Investment in Securities | 3.50M | -3.50M | ||||
| Other Investing Activities | 4.00K | -3.00K | -20.00K | |||
| Investing Cash Flow | -8.00K | -8.00K | 1.00K | 3.47M | -3.59M | -17.00K |
| Issuance of Common Stock | 4.55M | 4.55M | 11.30M | 4.34M | 3.87M | 11.90M |
| Other Financing Activities | -121.00K | -121.00K | -391.00K | -364.00K | -96.00K | |
| Financing Cash Flow | 4.43M | 4.43M | 10.91M | 3.98M | 3.77M | 11.90M |
| Foreign Exchange Rate Adjustments | 35.00K | 35.00K | -41.00K | 8.00K | -88.00K | 18.00K |
| Net Cash Flow | -3.21M | -3.21M | 738.00K | -903.00K | -7.52M | 10.36M |
| Free Cash Flow | -7.68M | -7.68M | -10.14M | -8.38M | -7.69M | -1.56M |
| Free Cash Flow Per Share | -6.03 | -6.03 | -10.90 | -12.29 | -13.36 | -4.98 |
| Levered Free Cash Flow | -3.87M | -3.87M | -7.83M | -4.26M | -3.80M | -467.62K |
| Unlevered Free Cash Flow | -3.87M | -3.87M | -7.83M | -4.26M | -3.80M | -467.62K |
| Change in Working Capital | 1.34M | 1.34M | -781.00K | 1.91M | 1.09M | 273.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 2.64M | 22.84M | 27.75M | 10.73M | 14.24M | 26.49M |
| Enterprise Value | 2.65M | 22.17M | 27.43M | 6.05M | 5.97M | 25.50M |
| Last Close Price | 1.43 | 15.38 | 24.00 | 15.70 | 24.40 | 49.20 |
| PB Ratio | -14.64 | 10.74 | -6.10 | 2.44 | 2.94 | |
| P/TBV Ratio | 10.74 | 2.44 | 2.94 | |||
| Debt / Equity Ratio | -0.11 | -0.11 | 0.03 | -0.08 | 0.04 | |
| Net Debt / Equity Ratio | -0.00 | -0.00 | -1.28 | 1.42 | -1.18 | -1.23 |
| Net Debt / EBITDA Ratio | 0.00 | 0.00 | 0.34 | 0.21 | 0.65 | 3.71 |
| Net Debt / FCF Ratio | -0.00 | -0.00 | 0.33 | 0.30 | 0.90 | 7.11 |
| Quick Ratio | 0.08 | 0.08 | 1.78 | 0.81 | 4.18 | 18.83 |
| Current Ratio | 0.31 | 0.31 | 2.21 | 0.84 | 4.28 | 19.12 |
| Return on Equity (ROE) | -2,174.97% | -2,174.97% | -2,478.15% | -494.83% | -141.31% | -66.63% |
| Return on Assets (ROA) | -247.30% | -247.30% | -159.50% | -138.15% | -68.90% | -30.56% |
| Return on Capital Employed (ROCE) | 745.00% | 745.00% | -383.40% | 4,397.40% | -176.20% | -27.60% |
| Earnings Yield | -610.62% | -48.71% | -36.79% | -94.21% | -73.67% | -12.16% |
| FCF Yield | -290.48% | -33.62% | -36.53% | -78.14% | -53.97% | -5.87% |
| Buyback Yield / Dilution | -36.98% | -36.98% | -36.38% | -18.56% | -84.27% | -13.12% |